Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

SpotDraft's Series B funding round, spearheaded by Vertex Ventures and Trident Partners, will accelerate the company's global ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 3.14% to $455.22 Tuesday, on what proved to be an all-around favorable ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

The contract lifecycle management platform aims to spend this year focusing on growing its talent and continuing to expand AI ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

Tesla stock fell Monday amid a fresh TSLA price-target cut as the EV giant's favorability has slumped. TSLA stock dived over ...

An increase in high-fat, high-fructose foods in people's diets has contributed to a dramatic increase in type 2 diabetes.

Taser maker Axon sees AI-related sales take off and its drone business gain momentum. Axon stock is near a buy point.